People with psoriasis are one step closer to another oral treatment option.
Tofacitinib, which is taken as a pill, can successfully treat moderate to severe plaque psoriasis, according to results from two Phase III trials released this week.
The trials, which tested the safety and efficacy of two separate doses of the drug, showed that tofacitinib was more effective than a placebo at reducing psoriasis severity. After 16 weeks, a significant number of patients in the trials achieved a 75 percent reduction in severity, and an assessment of "clear" or "almost clear" skin. Each trial enrolled more than 900 patients. No new safety concerns were raised by the trials.
Pfizer, the manufacturer of tofacitinib, plans to submit these results, along with the results of three other trials, by early 2015 as part of a drug approval application to the U.S. Food and Drug Administration.
Tofacitinib targets Janus kinase, an enzyme linked to psoriasis inflammation. It is currently available in the U.S. under the brand name of Xeljanz for the treatment of rheumatoid arthritis.
Learn more about psoriatic disease treatments in the drug pipeline.
Driving discovery, creating community
For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.